Asahi Kasei (TSE:3407) is back in focus after its therapeutics arm secured U.S. FDA approval for HOVILPRI pritelivir in refractory herpes simplex virus infections, and it has also started a Phase 2a trial for BK virus drug candidate AIC468.
Recent price action suggests investors are reacting to these healthcare milestones. Asahi Kasei’s 1 day share price return of 2.27% and year to date share price return of 12.85% sit alongside a 1 year total shareholder return of 37.97%, which indicates that momentum has been building over a longer horizon.
Scan for other healthcare and antiviral stories with similar momentum by checking the hand picked 10 healthcare AI stocks, which could sit alongside Asahi Kasei on your watchlist.
Asahi Kasei now has fresh momentum from its therapeutics wins and a long record across materials, homes, and healthcare. The key tension is simple: does the current share price fairly reflect that mix of strengths yet?
Most Popular Narrative: 18% Undervalued
Analysts following Asahi Kasei see more value than the market price of ¥1,602.5 suggests, with a narrative fair value of about ¥1,956 that leans on its push into specialty pharma and advanced materials.
Integration of Asahi Kasei Therapeutics, Veloxis Pharmaceuticals, Calliditas Therapeutics, and AiCuris under one global specialty pharmaceutical platform with a net sales target of ¥300 billion by fiscal 2030 can create scale in R&D, commercialization, and pricing, which may support higher revenue and earnings over time.
See why 1 investors see Asahi Kasei as 18% undervalued.
Result: Fair Value of ¥1,956.67 (UNDERVALUED)
Still, the narrative can unravel if Asahi Kasei struggles to scale newer pharma and battery lines, or if earnings land closer to the lower analyst forecasts.
Find out about the key risks to this Asahi Kasei narrative.
Next Steps
If this Asahi Kasei story feels optimistic on balance, consider acting promptly and stress test it against the underlying numbers yourself. You can start by checking the 5 key rewards
Looking for more investment ideas beyond Asahi Kasei?
Want a wider bench of opportunities alongside Asahi Kasei? Put the Simply Wall Street Screener to work and let it surface ideas you might otherwise miss.
- Target stability by scanning a list of solid balance sheet and fundamentals (21 results) that can help anchor your portfolio when sentiment swings.
- Chase potential mispricing by reviewing a 14 high quality undervalued stocks that line up strong fundamentals with prices that do not fully reflect them.
- Spot future standouts early by checking a 73 high quality undiscovered gems before they land on everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com